Table 1.
FDA approved immune checkpoint inhibitors.
| Drug | Immune Checkpoint Targeted | Year of Initial FDA Approval | Approved For: |
|---|---|---|---|
| Ipilimumab (Yervoy) | CTLA4 | 2011 | Unresectable or metastatic melanoma; cutaneous melanoma; renal cell carcinoma (in combination with Nivolumab) |
| Nivolumab (Opdivo) | PD1 | 2014 | Melanoma; Metastatic non-small cell lung cancer; Metastatic small cell lung Cancer; Advanced renal cell carcinoma; Hodgkin lymphoma; head and neck squamous cell carcinoma; advanced/metastatic urothelial cancer; colorectal cancer; hepatocellular carcinoma; |
| Pembrolizumab (Keytruda) | PD1 | 2014 | Melanoma; non-small cell lung cancer; small cell lung cancer; head and neck squamous cell carcinoma; Hodgkin lymphoma; primary mediastinal large B-cell lymphoma; urothelial carcinoma; gastric cancer; esophageal cancer; cervical cancer; hepatocellular carcinoma; Merkel cell carcinoma; renal cell carcinoma; endometrial carcinoma |
| Atezolizumab (Tecentriq) | PD-L1 | 2016 | Urothelial carcinoma; non-small cell lung cancer; Triple negative breast cancer; Small cell lung cancer |
| Avelumab (Bavencio) | PD-L1 | 2017 | Metastatic Merkel cell carcinoma; urothelial carcinoma; advanced renal cell carcinoma (in combination with axitinib) |
| Durvalumab (Imfinzi) | PD-L1 | 2017 | Advanced/metastatic urothelial carcinoma; unresectable stage III non-small cell lung cancer |